Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

12-06-2019 | Urothelial cancer | Video | Article

Expert comment: Phase II trial of enfortumab vedotin in urothelial cancer

print
PRINT
insite
SEARCH

ASCO expert Robert Dreicer gives his quick take on why the enfortumab vedotin data reported at the meeting hold so much promise for advanced urothelial carcinoma patients who have progressed on prior therapy (1:25).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

print
PRINT
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits